

Substitute for form 1443-P 70

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

*Complete if Known*

Application Number	10/801,078
Filing Date	March 15, 2004
First Named Inventor	Krzysztof Palczew
Art Unit	1612
Examiner Name	G. Huang
Attorney Docket Number	029060-000200US

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPPI 609. Draw and through citation if not in conformance and not considered. Include copy of form with next communication to applicant. Applicant's unique citation designator (reference number optional). See Kinds Codes and USPTO Patent Documents in [www.uspto.gov](http://www.uspto.gov) or MPPI 601.64. \*Enter Office that issues the document by the two-letter code (WIPO Standards ST 2). For European patent documents, the indication of the year of the term of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. \*Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to examine and require a benefit by the public when it is to be used by the USPTO to process an application. Confidentiality is guaranteed by 35 U.S.C. 122 and 37 CFR 1.14. The respondent is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND**  
**TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			Application Number	10/801,078	
			Filing Date	March 15, 2004	
			First Named Inventor	Krzysztof Palczewski et al.	
			Art Unit	1612	
			Examiner Name	G. Huang	
Sheet	2	of	2	Attorney Docket Number	029060-000200US

## NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AD	ACLAND et al., "Long-Term Restoration of Rod and Cone Vision by Single Dose rAAV-Mediated Gene Transfer to the Retina in a Canine Model of Childhood Blindness," <u>Mol. Therapy</u> , 12(6):1072-1082 (December, 2005)	
	AE	BATTEN et al., "Rheumatological and rAAV Gene Therapy Rescue of Visual Functions in a Blind Mouse Model of Leber Congenital Amaurosis," <u>PLoS Medicine</u> , 2(11):1-13(November, 2005)	
	AF	CORSON et al., "Sensitization of Bleach Rod Photoreceptors by 11-cis-locked Analogues of Retinal," <u>Proc. Natl. Acad. Sci. USA</u> , 87:6823-6827 (September, 1990)	
	AG	CRESCITELLI and PEARLMAN, "Can Isorhodopsin be Produced in the Living Rat?" <u>Vision Res.</u> , 13:2535-2525 (1973)	
	AH	JACOBSON et al., "Retinal Degenerations with Truncation Mutations in the Cone-Rod Homeobox (CRX) Gene," <u>Invest. Ophthalmol. Vis. Sci.</u> , 39(12): 2417-2426 (November, 1988)	
	AI	JACOBSON et al., "Identifying Photoreceptors in Blind Eyes Caused by RPE65 Mutations: Prerequisite for Human Gene Therapy Success," <u>Proc. Natl. Acad. Sci. USA</u> , 102(17):6177-6182 (April 26, 2005)	
	AJ	MATSUKAWA et al., "Role of Purpurin as a Retinol-Binding Protein in Goldfish Retina During the Early Stage of Optic Nerve Regeneration: Its Priming Action on Neurite Outgrowth," <u>J. Neurosci.</u> , 24(38):8346-8353 (September, 2004)	
	AK	NAKAMURA et al., "A High Association with Cone Dystrophy in <i>Fundus Albipunctatus</i> Caused by Mutations of the RDH5 Gene," <u>Invest. Ophthalmol. Vis. Sci.</u> , 41(12):3925-3932 (November, 2000)	
	AL	NOORWEZ et al., "Retinoids Assist the Cellular Folding of the Autosomal Dominant <i>Retinitis Pigmentosa</i> Opsin Mutant P23H," <u>J. Biol. Chem.</u> , 279(16) 16278-16284 (2004)	
	AM	SIBULESKY et al., "Safety of <7500 RE (<25000 IU) Vitamin A Daily in Adults with <i>Retinitis Pigmentosa</i> ," <u>Am. J. Clin. Nutr.</u> , 69:656-63 (1999)	
	AN	WEISER and SOMORJAI, "Bioactivity of Cis and Trans Isomers of Vitamin A Esters," <u>Internat. J. Vit. Nutr.</u> , 62:201-208 (1992)	
	AO	<u>www.wrongdiagnosis.com</u> "Symptom: Night Blindness," pgs. 1-13 (6/3/2008)	
Examiner Signature		Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 509. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English Language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2